Current Neurology and Neuroscience Reports

, Volume 12, Issue 5, pp 528–536 | Cite as

Diagnosis and Management of Behavioral Issues in Frontotemporal Dementia

  • Masood Manoochehri
  • Edward D. Huey
Dementia (KS Marder, Section Editor)


Frontotemporal lobar degeneration is an umbrella term for several different disorders. In behavioral variant frontotemporal dementia (bvFTD), patients show deterioration in cognition and social behavior. New diagnostic criteria proposed by the International Behavioral Variant FTD Consortium provide greater sensitivity in diagnosing bvFTD. Current pharmacological management of symptoms relies on medications borrowed from treating Alzheimer’s disease (AD) and psychiatric disorders. The evidence for using AD medications such as acetylcholinesterase inhibitors is questionable. Psychiatric medications can be helpful. Trazodone or SSRIs can have some efficacy in reducing disinhibition, repetitive behaviors, sexually inappropriate behaviors, and hyperorality. Small doses of atypical antipsychotics may be helpful in decreasing agitation and verbal outbursts. Nonpharmacological management includes caregiver education and support and behavioral interventions. While symptomatic treatments are likely to remain important behavior management tools, targeting the underlying pathology of bvFTD with disease-modifying agents will hopefully be the future of treatment.


FTLD Frontotemporal lobar degeneration bvFTD Frontotemporal dementia Diagnosis Differential diagnosis Treatment 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of outstanding importance

  1. 1.
    Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Rascovsky K, Hodges JR, Kipps CM, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord. 2007;21:S14–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Mendez MF, Shapira JS, McMurtray A, et al. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64:830–5.PubMedCrossRefGoogle Scholar
  4. 4.
    •• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77. This paper presents new criteria for diagnosing bvFTD. The paper demonstrates that the criteria are more sensitive and presents data on the relative prevalance on behavioral symptoms in pathologically confirmed cases.PubMedCrossRefGoogle Scholar
  5. 5.
    Mourik JC, Rosso SM, Niermeijer MF, et al. Frontotemporal dementia: behavioral symptoms and caregiver distress. Dement Geriatr Cogn Disord. 2004;18:299–306.PubMedCrossRefGoogle Scholar
  6. 6.
    Adenzato M, Cavallo M, Enrici I. Theory of mind ability in the behavioural variant of frontotemporal dementia: an analysis of the neural, cognitive, and social levels. Neuropsychologia. 2010;48:2–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Rankin KP, Gorno-Tempini ML, Allison SC, et al. Structural anatomy of empathy in neurodegenerative disease. Brain. 2006;129:2945–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Huey ED, Armstrong N, Momeni P, Grafman J. Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008;12:1367–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Ikeda M, Brown J, Holland AJ, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;73:371–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Mendez MF, Foti DJ. Lethal hyperoral behaviour from the Kluver-Bucy syndrome. J Neurol Neurosurg Psychiatry. 1997;62:293–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Piguet O. Eating disturbance in behavioural-variant frontotemporal dementia. J Mol Neurosci. 2011;45:589–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Piguet O, Petersen A, Yin Ka Lam B, et al. Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol. 2011;69:312–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Carey CL, Woods SP, Damon J, et al. Discriminant validity and neuroanatomical correlates of rule monitoring in frontotemporal dementia and Alzheimer's disease. Neuropsychologia. 2008;46:1081–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Lillo P, Hodges JR. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J Clin Neurosci. 2009;16:1131–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Levy ML, Miller BL, Cummings JL, et al. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol. 1996;53:687–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236:43–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Bozeat S, Gregory CA, Ralph MA, Hodges JR. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000;69:178–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Liscic RM, Storandt M, Cairns NJ, Morris JC. Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol. 2007;64:535–40.PubMedCrossRefGoogle Scholar
  20. 20.
    • Mathias JL, Morphett K. Neurobehavioral differences between Alzheimer's disease and frontotemporal dementia: a meta-analysis. J Clin Exp Neuropsychol. 2010;32:682–98. This paper reviews studies over a 14-year period that included AD and FTD neurobehavioral measures. The paper finds that FTD-specific scales are best at discriminating between AD and FTD.PubMedCrossRefGoogle Scholar
  21. 21.
    Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc. 2000;6:460–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol. 2004;17:185–90.PubMedGoogle Scholar
  23. 23.
    De Deyn PP, Engelborghs S, Saerens J, et al. The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. Int J Geriatr Psychiatry. 2005;20:70–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Grace, J.a.M., P.F., Frontal Systems Behavioral Scale: Professional Manual. 2001, Lutz, FL: Psychological Assessment Resources, Inc.Google Scholar
  25. 25.
    National Alzheimer's Coordinating Center. Available at Accessed May 2012.
  26. 26.
    Chow TW, Pio FJ, Rockwood K. An international needs assessment of caregivers for frontotemporal dementia. Can J Neurol Sci. 2011;38:753–7.PubMedGoogle Scholar
  27. 27.
    Woolley JD, Khan BK, Murthy NK, et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72:126–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Salmon E, Perani D, Collette F, et al. A comparison of unawareness in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2008;79:176–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Koenigs M, Huey ED, Calamia M, et al. Distinct regions of prefrontal cortex mediate resistance and vulnerability to depression. J Neurosci. 2008;28:12341–8.PubMedCrossRefGoogle Scholar
  30. 30.
    McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Lopez OL, Gonzalez MP, Becker JT, Reynolds CF, et al. Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:154–61.Google Scholar
  32. 32.
    Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135:693–708.PubMedCrossRefGoogle Scholar
  33. 33.
    Panegyres PK, Graves A, Frencham KA. The clinical differentiation of fronto-temporal dementia from psychiatric disease. Neuropsychiatr Dis Treat. 2007;3:637–45.PubMedGoogle Scholar
  34. 34.
    Rankin KP, Santos-Modesitt W, Kramer JH, et al. Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. J Clin Psychiatry. 2008;69:60–73.PubMedCrossRefGoogle Scholar
  35. 35.
    • Bei H, Ross L, Neuhaus J, et al. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2010;25:128–33. This paper uses a large data set to determine the prevalence of medications used to treat bvFTD.CrossRefGoogle Scholar
  36. 36.
    de Vugt ME, Riedijk SR, Aalten P, et al. Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord. 2006;22:35–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Lopez-Pousa S, Calvo-Perxas L, Lejarreta S, et al. Use of antidementia drugs in frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen, 2012.Google Scholar
  38. 38.
    Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–85.PubMedCrossRefGoogle Scholar
  42. 42.
    Kerchner GA, Tartaglia MC, Boxer A. Abhorring the vacuum: use of Alzheimer's disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11:709–17.PubMedCrossRefGoogle Scholar
  43. 43.
    Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev, 2005: CD003154.Google Scholar
  44. 44.
    Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Diehl-Schmid J, Forstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23:754–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Vercelletto M, Boutoleau-Bretonniere C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23:749–59.PubMedGoogle Scholar
  48. 48.
    Chow TW, Graff-Guerrero A, Verhoeff NP, et al. Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat. 2011;7:415–24.PubMedCrossRefGoogle Scholar
  49. 49. Memantine (10 mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia. Available at Accessed May 2012
  50. 50.
    Sjogren M, Minthon L, Passant U, et al. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging. 1998;19:379–84.PubMedCrossRefGoogle Scholar
  51. 51.
    Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002;58:1489–93.PubMedCrossRefGoogle Scholar
  52. 52.
    Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172:400–8.CrossRefGoogle Scholar
  53. 53.
    Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry, 2011.Google Scholar
  56. 56.
    Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17:117–21.PubMedCrossRefGoogle Scholar
  58. 58.
    Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–9.PubMedCrossRefGoogle Scholar
  59. 59.
    O'Brien JT, Burns A, B.A.P.D.C. Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:997–1019.PubMedCrossRefGoogle Scholar
  60. 60.
    Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69.PubMedCrossRefGoogle Scholar
  61. 61.
    Curtis RC, Resch DS. Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Fellgiebel A, Muller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Mendez MF, Lipton A. Emergent neuroleptic hypersensitivity as a herald of presenile dementia. J Neuropsychiatry Clin Neurosci. 2001;13:347–56.PubMedCrossRefGoogle Scholar
  65. 65.
    Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168–78.PubMedCrossRefGoogle Scholar
  66. 66.
    Ikeda M, Tanabe H, Horino T, et al. Care for patients with Pick's disease–by using their preserved procedural memory. Seishin Shinkeigaku Zasshi. 1995;97:179–92.PubMedGoogle Scholar
  67. 67.
    Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2007;21:S64–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Mioshi E, Foxe D, Leslie F, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord, 2012.Google Scholar
  69. 69.
    Knopman DS, Kramer JH, Boeve BF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131:2957–68.PubMedCrossRefGoogle Scholar
  70. 70.
    Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Gennatas ED, Cholfin JA, Zhou J, et al. COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures. Neurology. 2012;78:1663–9.PubMedCrossRefGoogle Scholar
  72. 72. Effects of Tolcapone on Frontotemporal Dementia. Available at Accessed May 2012.
  73. 73.
    Finger EC. New potential therapeutic approaches in frontotemporal dementia: oxytocin, vasopressin, and social cognition. J Mol Neurosci. 2011;45:696–701.PubMedCrossRefGoogle Scholar
  74. 74.
    Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain. 2011;134:2493–501.PubMedCrossRefGoogle Scholar
  75. 75. Safety Study of Intranasal Oxytocin in Frontotemporal Dementia. Available at Accessed May 2012.
  76. 76.
    Coccaro EF, Kavoussi RJ, Hauger RL, et al. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Arch Gen Psychiatry. 1998;55:708–14.PubMedCrossRefGoogle Scholar
  77. 77.
    Prichard ZM, Mackinnon AJ, Jorm AF, Easteal S. AVPR1A and OXTR polymorphisms are associated with sexual and reproductive behavioral phenotypes in humans. Mutation in brief no. 981. Online. Hum Mutat. 2007;28:1150.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, The Gertrude H. Sergievsky CenterColumbia UniversityNew YorkUSA

Personalised recommendations